Method of treating attention deficit disorders with d-threo methylphenidate

Abstract

Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.

1 . A method of treating Attention Deficit Disorder on a daily basis while reducing side effects associated with the administration of racemic threo methylphenidate which comprises administrating on a daily basis to a human in need thereof an amount of D-threo methylphenidate or a pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, wherein the amount administered is effective to treat Attention Deficit Disorder while reducing side effects associated with racemic threo methylphenidate.  
     
     
         2 . The method according to  claim 1  wherein the amount administered is 5 mg to 50 mg per day.  
     
     
         3 . The method according to  claim 2  wherein the amount administered is 5 mg per day.  
     
     
         4 . The method according to  claim 1  wherein the amount of said d-threo methylphenidate or a pharmaceutically equivalent salt thereof is greater than 90% of the total amount of methylphenidate.  
     
     
         5 . The method according to  claim 4  wherein the amount of said d-threo methylphenidate or a pharmaceutically equivalent salt thereof is greater than 99% of the total amount of methylphenidate.  
     
     
         6 . The method according to  claim 1  wherein the side effects are anorexia, weight loss, insomnia, dizziness, or dysphoria.  
     
     
         7 . The method according to  claim 1  wherein the side effect is a euphoric effect.  
     
     
         8 . The method according to  claim 1  wherein the side effect is drug abuse potential.  
     
     
         9 . The method according to  claim 1  wherein the amount of D-threo methylphenidate enhances therapeutic activity compared to racemic methylphenidate.  
     
     
         10 . The method according to  claim 1  wherein the administration is daily.  
     
     
         11 . The method according to  claim 1  wherein the administration is one to four times per day.  
     
     
         12 . The method according to  claim 1  wherein said amount of D-threo methylphenidate or pharmaceutically acceptable salt thereof comprises a carrier or diluent.